Dilantin is expensive primarily because it occupies a unique position in the drug market: its patent expired decades ago, but medical concerns about switching patients to generic versions keep demand for the brand alive, giving the manufacturer unusual pricing power. A 90-count supply of brand-name Dilantin 100mg runs around $210 without insurance, though discount coupons can bring that closer to $63. The generic version of the same active ingredient, phenytoin, costs a fraction of that.
The Narrow Therapeutic Index Problem
The core reason Dilantin commands a premium comes down to biology. Phenytoin, the active drug in Dilantin, is classified as a narrow therapeutic index (NTI) drug. That means the difference between a dose that controls seizures and one that causes toxicity is unusually small. The FDA estimates phenytoin’s toxic-to-effective ratio at just 2.7, leaving very little margin for error. Doctors typically adjust doses in increments of less than 20%, and patients on phenytoin require regular blood monitoring to make sure levels stay in a safe range.
This matters for pricing because even slight differences between the brand and a generic version can cause problems. If a patient who’s been stable on Dilantin switches to a generic and absorbs the drug a little differently, their blood levels could drift into a range that’s either ineffective or dangerous. For this reason, many neurologists are reluctant to switch a stable patient, and some states have specific laws restricting pharmacists from automatically substituting generic versions of NTI drugs. A survey of pharmacists found that while 82% would substitute a generic NTI drug for a new prescription, only 60% would do so on a refill for an existing patient. That reluctance creates a captive customer base for the brand.
Expired Patents, Persistent Pricing Power
Dilantin has no unexpired patents or market exclusivity protections. Phenytoin has been available as a generic for years. Under normal market conditions, generic competition drives brand-name prices down. But NTI drugs don’t follow normal market rules. Because so many patients and prescribers resist switching, the brand retains a loyal customer base that isn’t particularly price-sensitive. Manufacturers know these patients will keep buying regardless, which removes the usual competitive pressure that generics exert.
The price gap is significant. Brand-name Dilantin costs roughly $1.86 to $2.04 per capsule without insurance, putting a 100-capsule supply between $186 and $204. Generic phenytoin, by comparison, can cost as little as $0.10 per unit in liquid form. Even comparing capsule to capsule, generic phenytoin runs far less than the brand. For patients whose doctors specifically prescribe “Dilantin” with no substitution allowed, that price gap is unavoidable without a discount program.
A History of Aggressive Price Increases
Dilantin’s pricing hasn’t always been this high. The most dramatic example of how phenytoin pricing can be manipulated played out in the UK. In September 2012, Pfizer stopped selling its branded phenytoin capsules (sold as Epanutin in the UK) directly and instead channeled them through a smaller company called Flynn Pharma. By “de-branding” the drug, the companies removed it from a government price regulation scheme. Overnight, the price of a 100mg pack jumped from £2.83 to £67.50, an increase of roughly 2,600%. NHS spending on phenytoin capsules surged from about £2 million a year to £50 million in a single year.
Pfizer’s wholesale prices to Flynn were between 780% and 1,600% higher than what Pfizer had previously charged. Flynn then marked them up further before selling to pharmacies. The UK’s Competition and Markets Authority fined both companies, and in November 2024, a tribunal confirmed that both Pfizer and Flynn had abused their dominant market positions by charging excessive prices between 2012 and 2016, resulting in fines of £69 million. While this case was specific to the UK market, it illustrates how phenytoin’s captive patient population makes it a target for aggressive pricing strategies.
Supply Chain Concentration Adds Risk
Older drugs like phenytoin also face supply chain vulnerabilities that can affect pricing. When only a small number of manufacturers produce a drug or its key starting materials, there’s little competitive pressure to lower prices and a higher risk of shortages that push costs up further. Nearly half of the most vulnerable medicines in the US rely on at least one critical ingredient manufactured exclusively in a single country. Even when multiple companies make the finished product, they sometimes all depend on the same sole supplier for a raw material upstream, creating hidden fragility. A disruption at one facility can tighten supply across the entire market and drive prices higher.
For a drug like phenytoin, which has been on the market for decades, the number of companies willing to invest in manufacturing it is limited. Profit margins on older generics are thin, which discourages new competitors from entering the market. The result is a small number of suppliers with outsized control over availability and pricing.
How to Reduce What You Pay
If you’re paying out of pocket for brand-name Dilantin, the most straightforward option is asking your doctor whether switching to generic phenytoin is safe in your specific case. For patients starting phenytoin for the first time, a generic is typically appropriate and dramatically cheaper. For patients who’ve been stable on brand-name Dilantin for years, the decision is more nuanced and depends on seizure history, sensitivity to dose changes, and how closely blood levels can be monitored during a transition.
Discount programs can also cut costs substantially. GoodRx coupons, for example, can bring the price of 90 brand-name Dilantin capsules from over $210 down to around $63. Manufacturer assistance programs and state pharmaceutical assistance programs are additional options worth exploring, particularly for patients without insurance or with high-deductible plans. The price you see at the pharmacy counter is rarely the only price available.